Description
Brief comparison of 5-Amino-1MQ, MOTS-c, and AOD-9604
All three are researched for metabolic/fat-loss effects but differ sharply in chemistry, mechanism, and evidence strength.
| Aspect | 5-Amino-1MQ | MOTS-c | AOD-9604 |
|---|---|---|---|
| Type | Small molecule (quinolinium derivative); not a peptide | Mitochondrial-derived peptide (16 amino acids) | Modified growth-hormone fragment (C-terminal residues 177–191 + Tyr) |
| Primary mechanism | Inhibits NNMT enzyme → preserves NAD+ and SAM in adipocytes → raises energy expenditure and reduces lipogenesis | Activates AMPK and related metabolic pathways; acts as a mitochondrial signaling peptide that improves energy homeostasis | Stimulates lipolysis (fat breakdown) with minimal or no rise in IGF-1 |
| Main researched effects | Reduced adiposity/fat mass, improved metabolic markers (preclinical); may support body recomposition without major appetite change | Improved insulin sensitivity, glucose handling, fat oxidation, and exercise capacity; broader metabolic flexibility | Targeted fat reduction (especially in some early studies); potential body-composition support |
| Evidence level | Almost entirely preclinical (cells + rodent models); very limited human data | Mostly preclinical; some early human/observational signals | Early clinical studies + Phase trials for obesity (results mixed/insufficient for approval as a weight-loss agent) |
| Administration | Oral (small molecule with decent bioavailability) | Typically subcutaneous injection | Subcutaneous injection (oral forms investigated) |
| Key distinction | Enzyme-level metabolic “brake” removal focused on fat cells | Mitochondrial/AMPK-centered energy sensing and whole-body metabolic reprogramming | Direct lipolytic signaling derived from the GH molecule |
Summary
- 5-Amino-1MQ works by blocking a specific enzyme (NNMT) that slows fat-cell metabolism.
- MOTS-c works higher up the cellular energy-sensing cascade (AMPK/mitochondrial signaling).
- AOD-9604 works via a lipolysis pathway inherited from growth hormone.
None is FDA-approved for general weight loss or metabolic treatment; all remain investigational/research compounds with the strongest human data belonging to AOD-9604 (though still limited and mixed). They are sometimes stacked in research contexts because their mechanisms are complementary rather than overlapping.
